Faculty Opinions recommendation of Hypertensive disorders in pregnancy: screening by uterine artery Doppler imaging and blood pressure at 11-13 weeks.

Author(s):  
Amar Bhide ◽  
Rohan D'Souza
2010 ◽  
Vol 30 (3) ◽  
pp. 216-223 ◽  
Author(s):  
Leona C. Y. Poon ◽  
Violeta Stratieva ◽  
Silvia Piras ◽  
Solmaz Piri ◽  
Kypros H. Nicolaides

2009 ◽  
Vol 34 (2) ◽  
pp. 142-148 ◽  
Author(s):  
L. C. Y. Poon ◽  
I. Staboulidou ◽  
N. Maiz ◽  
W. Plasencia ◽  
K. H. Nicolaides

ESC CardioMed ◽  
2018 ◽  
pp. 2872-2874
Author(s):  
Renata Cifkova

Hypertensive disorders in pregnancy are the most common medical complications affecting 5–10% of pregnancies worldwide. This chapter discusses the following topics: diagnosis of hypertension, definition and classification of hypertension in pregnancy, additional laboratory tests, management of hypertension in pregnancy, pharmacological management of hypertension in pregnancy, delivery induction, blood pressure postpartum and lactation, and prognosis after pregnancy.


Nutrients ◽  
2020 ◽  
Vol 12 (2) ◽  
pp. 378 ◽  
Author(s):  
Silvia Fogacci ◽  
Federica Fogacci ◽  
Arrigo F.G. Cicero

The aim of the present critical review is to summarize the available clinical evidence supporting the use of some dietary supplements that have been shown to lower blood pressure in hypertensive pregnant women. A systematic search strategy was carried out to identify trials in MEDLINE (National Library of Medicine, Bethesda, Maryland, MD, USA; January 1980 to September 2019) and the Cochrane Register of Controlled Trials (The Cochrane Collaboration, Oxford, UK). The terms ‘nutraceuticals’, ‘dietary supplements’, ‘pregnancy’, ‘pre-eclampsia’, ‘clinical trial’, and ‘human’ were incorporated into an electronic search strategy. The references of the identified studies and review articles were reviewed to look for additional studies of interest. We preferably selected papers that reported recent comprehensive reviews or meta-analysis, or original clinical trials of substances with blood pressure-lowering or vascular protective effect in pregnancy. There is a relative body of evidence that supports the use of calcium, vitamin D, folic acid, and resveratrol in preventing the development of hypertensive disorders in pregnancy, and evidence supporting drug treatment too. Further clinical research is advisable to identify the dosage and timing of the supplementation, the group of women that might benefit the most from this approach, and the nutraceuticals with the best cost-effectiveness and risk-benefit ratio for widespread use in clinical practice.


2018 ◽  
Vol 6 (4) ◽  
Author(s):  
Tunau KA ◽  
Sulaiman R ◽  
Garba JA ◽  
Aliyu FB ◽  
Panti AA ◽  
...  

Background: Hypertensive disorders in pregnancy are multi-organ, heterogeneous disorder of pregnancy associated with significant maternal and neonatal morbidity and mortality. Pre-eclampsia is a condition which typically occurs after 20 weeks of gestation and is characterized by high blood pressure and significant proteinuria. Objective: The aim of the study was to find out the outcome of pregnancies complicated by pre-eclampsia in the teaching hospital in Sokoto, North-West Nigeria. Methods: A five-year retrospective study on the presentation and outcome of management of pre-eclampsia carried out in Usmanu Danfodiyo University Teaching Hospital (UDUTH) between 1st January 2010 and 31st December 2014.


2018 ◽  
Vol 03 (02/03) ◽  
pp. 068-078
Author(s):  
Lalita Nemani

Abstract Hypertension in pregnancy is defined as systolic blood pressure (SBP) ≥ 140 mm Hg or diastolic blood pressure (DBP) ≥ 90 mm Hg or both on two different occasions at least 6 hours apart. Severe hypertension is SBP ≥ 160 mm Hg or DBP ≥ 110 mm Hg. Hypertension is the most common medical problem in pregnancy and one of the major causes of maternal and perinatal mortality and morbidity. Hypertensive disorders in pregnancy (HDP) are classified as (1) chronic hypertension, (2) chronic hypertension with superimposed preeclampsia, (3) preeclampsia-eclampsia, and (4) gestational hypertension. HDP contributes to increased risk of hypertension, stroke, and maternal cardiovascular disease (CVD) in later life. HDP can be considered as a failed cardiovascular stress test identifying women susceptible to CVD in later life. Further research is required to identify the mechanisms in HDP that contribute to CVD in later life so as to initiate appropriate prevention measures.


Sign in / Sign up

Export Citation Format

Share Document